Treatment of type 2 diabetes with incretin-based therapies

The Lancet

Volumn 373, Issue 9662, 2009, Pages 438-439

  Madsbad, Sten ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN;

ABSENCE OF SIDE EFFECTS; APPETITE; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG DEGRADATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VOMITING; WEIGHT REDUCTION;

EID: 59349108585     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61247-7     Document Type: Note

References (14)

1. Garber A., Henry R., Ratner R., et al., on behalf of the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2008) 10.1016/S0140-6736(08)61246-5 published online Sept 25.
2. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007) 1409-1439
3. Holst J.J., Deacon C.F., Vilsbøll T., Krarup T., and Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 14 (2008) 161-168
4. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
5. Marre M., Shaw J., Brandle M., et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. Diabetes 57 suppl 1 (2008) A4 (abstr).
6. Nauck M.A., Frid A., Hermansen K., et al. Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin. Diabetes 57 suppl 1 (2008) A150 (abstr).
7. Russell-Jones D., Vaag A., Schmitz O., et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes 57 suppl 1 (2008) A159-A160 (abstr).
8. Zinman B., Gerich J., Buse J., et al. Effect of the GLP-1 analog liraglutide on glycemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial. Diabetologia 51 suppl 1 (2008) S358-S359
9. Madsbad S., Krarup T., Deacon C.F., and Holst J.J. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 11 (2008) 491-499
10. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007) 194-206
11. Drucker D.J., Buse J.B., Taylor K., et al., for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 10.1016/S0140-6736(08)61206-4 published online Sept 8.
12. Richter B., Bandeira-Echtler E., Bergerhoff K., and Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2 (2008) CD006739.
13. US Food and Drug Administration. Exenatide (marketed as Byetta) Information (Aug 18, 2008). http://www.fda.gov/cder/drug/infopage/exenatide/default.htm (accessed Aug 27, 2008).
14. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972